The global immunofluorescence assay (IFA) market size was USD 2.45 billion in 2020 and is expected to register a CAGR of 6.3% during the forecast period.
The global immunofluorescence assay (IFA) market size was USD 2.45 billion in 2020 and is expected to register a CAGR of 6.3% during the forecast period. Key factors driving market revenue growth are increasing prevalence of chronic diseases, rising investments in research facilities in healthcare sector, and rising availability of advanced immunofluorescence assay kits and reagents. Increasing investment on R&D to accelerate product development and growing focus on improving healthcare facilities are factors also expected to contribute to revenue growth of the market going ahead.
Immunofluorescence assay is a microscopic method primarily used on microbiological samples. The technique uses specificity of antibodies to their antigens to target fluorescent dyes to particular biomolecules within a cell. This enables visualizing distribution of target molecules in the sample. Immunofluorescence is the primary example of immunostaining, which is a technique that uses antibodies to stain proteins. It is used for tissue cross sections, cultured cell lines, and to elucidate the distribution of proteins, glycans, and biomolecules. Immunofluorescence is a common laboratory technique based on the use of specific antibodies that are chemically conjugated to fluorescent dyes.
Inquiry Before Buying@ https://qyresearchmedical.com/submit-inquiry/118250
These labelled antibodies can be attached to cellular antigens, either directly or indirectly. The fluorescent dye is exposed to short wavelength and high energy light, which is then absorbed and emitted as a light of different wavelength. It can be visualized through fluorescence microscopy. Direct immunofluorescence utilizes a single antibody, which is conjugated to a fluorophore. Indirect immunofluorescence deploys two antibodies, wherein the primary antibody is unconjugated and secondary antibody is conjugated to a fluorophore against the primary antibody. Immunofluorescence assay is a standard virologic technique that is used to determine the presence of antibodies by their specificity to viral antigens expressed in the infected cells.
Indirect immunofluorescence has been extensively used as a confirmatory assay in the diagnosis of HIV AIDS in the past and is still being used in laboratories. Immunofluorescence assays have also been widely used to develop antibodies against SARS-CoV-2 to enable efficient detection, which will help curb the spread of the virus. This trend is expected to prevail going ahead due to increasing cases of coronavirus infections worldwide.
Rapid advancements in medical facilities, increasing R&D activities in biopharmaceutical sector, progressing antibody-based therapies, and increasing collaborations between research institutes and biotechnology companies are expected to drive market growth over the forecast period. However, shortage of skilled professionals is expected to restrain market growth to a certain extent over the forecast period.
Market Dynamics:
Driver: Rising prevalence of chronic diseases globally is a key factor driving revenue growth of the market
Prevalence of chronic diseases has rapidly increased worldwide over the recent past and these diseases account for over half of the healthcare burden. Major chronic diseases such as cancers, diabetes, neurological disorders, autoimmune conditions, cardiovascular diseases, intestinal diseases, and lung disorders have significantly increased due to unhealthy dietary choices, sedentary lifestyle, obesity, increased alcohol consumption, and smoking. In addition, growing concerns about emerging viral diseases have prompted health organizations globally to establish research facilities that can study new viruses and prevent potential outbreaks.
These factors have boosted demand for immunofluorescence assays owing to ability to determine the distribution of glycans and proteins in a sample and detect viral antigens more efficiently. For instance, immunofluorescence assays have been extensively used in the detection of SARS-CoV-2 as they allow researchers and pathologists to rapidly visualize effects and dynamics of viral infections. This has provided a significant boost to drug discovery and development and is expected to contribute significantly to revenue growth of the market over the forecast period.
Related Reports:
- ORTHOBIOLOGICS MARKET: https://qyresearchmedical.com/report/orthobiologics-market-by-product-type-viscosupplementation-products-demineralized-bone-matrices-synthetic-orthobiologics-bone-morphogenic-protein-allografts-and-plasma-rich-protein-by-end-use-by-applicatio-st-to-2030/118242
- METABOLOMICS MARKET: https://qyresearchmedical.com/report/metabolomics-market-by-product-and-services-metabolomics-separation-tools-metabolomics-detection-tools-bioinformatics-tools-and-services-by-end-use-by-application-by-indication-and-by-region-forecast-to-2030/118241
Restraint: High costs of instruments used in immunofluorescence assays is a key market growth restraining factor
Imaging instruments and equipment such as fluorescence microscope and reagents and consumables used during the assays are expensive. Frequent purchase of these reagents and kits and regular maintenance of high-end instruments increase the expenditure, which is a key factor restraining market growth. In addition, lack of skilled professionals and technicians in histopathology laboratories is expected to restrain market growth to a certain extent over the forecast period.
Product Outlook:
Based on product, the global immunofluorescence assay (IFA) market is segmented into reagents, kits, antibodies, instruments, and consumables & accessories. The kits segment is expected to account for largest share in terms of revenue over the forecast period. Steady segment revenue growth is attributable to increasing development of complete solutions and rising demand for calibrated reagents and solutions from research institutes, Contract Research Organizations (CROs), and academic institutions. Increasing application of immunofluorescence assays in research and clinical diagnostics is expected to further boost demand for assay kits and contribute to revenue growth of this segment going ahead. Reagents segment is expected to register considerable growth during the forecast period owing to increasing demand and need for frequent repurchasing of reagents and controls.
Type Outlook:
Based on type, the global immunofluorescence assay (IFA) market is segmented into direct immunofluorescence and indirect immunofluorescence. Indirect immunofluorescence segment is expected to register significant revenue CAGR during the forecast period. Steady growth can be attributed to advantages offered by the technique such as enhanced flexibility, sensitivity, and higher signal amplification. One of the major advantages of indirect immunofluorescence assay is that one fluorescent anti-immunoglobulin antibody is sufficient for numerous primary antibodies, which eliminates the need to conjugate each new antibody individually. This drastically reduces the overall cost of the assay. Cost-effectiveness of this technique over direct immunofluorescence is also expected to contribute to revenue growth of this segment over the forecast period. In addition, secondary antibodies that are used in indirect immunofluorescence are relatively inexpensive as compared to primary antibodies, which is expected to contribute to revenue growth of this segment going ahead.
Disease Outlook:
Based on disease, the global immunofluorescence assay market is segmented into cancer, infectious diseases, cardiovascular diseases, autoimmune diseases, and others. Cancer accounted for significantly large revenue share in the global market in 2020 and is expected to register significantly steady revenue growth during the forecast period. Steady revenue growth can be attributed to rapidly rising prevalence of cancer across the globe, growing adoption of immunofluorescence techniques in diagnosis and screening of cancer, and increased sensitivity of this technique to detect cancer cells.
End-use Industry Outlook:
Based on end-use industry, the global immunofluorescence assay market is segmented into academic & research institutions, pharmaceutical & biotechnology companies, CROs, and hospitals & diagnostic centers. Pharmaceutical and biotechnology companies segment is expected to dominate other end-use segments over the forecast period owing to increasing application of immunofluorescence assays in drug discovery and development processes to study etiology of diseases, increasing deployment of laboratory automation technologies, and technological developments in immunofluorescence assays. In addition, growing demand for fluorescence microscopy and subsequent use of immunofluorescence samples in biotechnology and biopharmaceutical research is expected to drive revenue growth of this segment over the forecast period. Hospitals and diagnostics centers segment is also expected to register significant revenue growth owing to rising prevalence of chronic diseases, rising number of hospital admissions, and rapidly growing network of hospitals globally.
Regional Outlook:
Based on regional analysis, the market in North America is expected to account for largest share in terms of revenue over the forecast period. Growth can be attributed to rising prevalence of chronic and infectious diseases, growing patient pool of cardiovascular diseases due to unhealthy lifestyle and eating habits and diets, increasing R&D investment, development of state-of-the-art healthcare infrastructure, and rapid progress of drug research and development in countries in the region. In addition, increasing government funding, favorable reimbursement scenario, and high presence of key players are other factors expected to drive revenue growth of the market in the region.
Europe is expected to register steady revenue growth during the forecast period owing to increasing prevalence of cancer, rising drug research and development activities, and rapidly developing biotechnology sector in the region. Asia Pacific is expected to register rapid revenue CAGR over the forecast period, which is attributable to growing geriatric population, increasing investments to develop more advanced and modern healthcare facilities, rapid increase in research and development activities, and growing presence of key players in countries such as China, Japan, and India.
Competitive Landscape:
Competitive landscape of the global immunofluorescence assay market is intense and consolidated with key players operating both on regional and global levels. Key companies in the market are focusing on product advancements, extensive R&D activities, and strategic alliances such as mergers and acquisitions to cater to growing global demand and to gain a competitive edge in the market. Prominent companies in the market include Thermo Fisher Scientific, Inc., Merck KGaA, Danaher Corporation, Abcam Plc, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Werfen Company, Agilent Technologies, Cell Signaling Technology, Inc., MEDIPAN GmbH, Enzo Biochem, Inc., Becton, Dickinson and Company, Bruker Corporation, EpiGentek Group, and others.
Some key developments in the market:
- In July 2020, Ultivue, Inc. and OracleBio formed a collaborative partnership to accelerate personalized tumor characterization for drug research and development in translational and clinical oncology with the application of multiplex immunofluorescence staining and imaging.
- In April 2021, EUROIMMUN, which is an international provider of medical laboratory products for autoimmune and molecular genetic diagnostics and a PerkinElmer company, introduced EuroPattern Microscope Live compact immunofluorescence microscope. The new instrument enables ultrafast automated immunofluorescence image acquisition, pattern recognition, and titer estimation. It deploys novel laser focusing technology that acquires and interprets high-quality immunofluorescence images in less than two seconds.
Inquiry Before Buying@ https://qyresearchmedical.com/submit-inquiry/118250
Segments Covered in the Report:
This report offers historical data and forecasts revenue growth at a global, regional, and country level, and provides analysis of the market trends in each of the sub-segments from 2018 to 2030.
For this study, Reports and Data has segmented the global immunofluorescence assay market based on product, type, disease, end-use industry, and region:
Product Outlook (Revenue, USD Billion; 2018-2030)
- Reagents
- Kits
- Antibodies
- Instruments
- Consumables & Accessories
Type Outlook (Revenue, USD Billion; 2018-2030)
- Direct immunofluorescence
- Indirect immunofluorescence
Disease Outlook (Revenue, USD Billion; 2018-2030)
- Cancer
- Cardiovascular diseases
- Autoimmune diseases
- Infectious diseases
- Others
End-use Industry Outlook (Revenue, USD Billion; 2018-2030)
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- CROs
- Hospitals & Diagnostic Centers
Regional Outlook (Revenue, USD Billion; 2018-2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- Italy
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- U.A.E.
- South Africa
- Rest of MEA
Buy quantitative research Report at discounted price - USD 1500 https://qyresearchmedical.com/report/checkout/118250/1500
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
About Us
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL - http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/
https://twitter.com/qyresearchmedi